Published in Arterioscler Thromb Vasc Biol on July 01, 1998
Control of matrix metalloproteinase catalytic activity. Matrix Biol (2007) 2.18
Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest (2008) 2.16
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med (2003) 1.59
MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med (2005) 1.55
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol (2000) 1.33
The discoidin domain receptor tyrosine kinase DDR1 in arterial wound repair. J Clin Invest (2001) 1.25
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest (2005) 1.25
Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol (2003) 1.15
The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell (2007) 1.15
Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol (2001) 1.12
Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol (2001) 1.12
MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res (2009) 1.12
Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest (1998) 1.08
Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice. J Vasc Res (2009) 0.97
Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. J Exp Med (2004) 0.96
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution. J Surg Res (2007) 0.95
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline. Ann Vasc Surg (2010) 0.91
c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Am J Pathol (2007) 0.91
Patterns of kinase activation induced by injury in the murine femoral artery. J Surg Res (2007) 0.89
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J (2001) 0.89
Patterns of gelatinase activation induced by injury in the murine femoral artery. J Surg Res (2008) 0.87
Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid. J Biol Chem (2011) 0.86
Gene expression profiling of preovulatory follicle in the buffalo cow: effects of increased IGF-I concentration on periovulatory events. PLoS One (2011) 0.84
Three are better than one: plasminogen receptors as cancer theranostic targets. Exp Hematol Oncol (2013) 0.84
Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice. PLoS One (2010) 0.82
Role for Gβγ G-proteins in protease regulation during remodeling of the murine femoral artery. J Surg Res (2011) 0.82
Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice. Arthritis Rheumatol (2014) 0.81
Gαq G proteins modulate MMP-9 gelatinase during remodeling of the murine femoral artery. J Surg Res (2012) 0.80
Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol (2005) 0.80
Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia. J Thromb Haemost (2013) 0.79
Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration. J Surg Res (2015) 0.78
Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain. Biochemistry (2014) 0.76
Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting. Neural Regen Res (2015) 0.76
Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling. J Surg Res (2014) 0.75
Who are the proteolytic culprits in vascular disease? J Clin Invest (1999) 0.75
The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab (2017) 0.75
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 7.33
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (1983) 5.27
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem (1982) 3.95
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost (1980) 3.44
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet (1997) 3.40
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene (1999) 3.00
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem (1981) 2.80
Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost (2005) 2.70
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol (2000) 2.53
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 2.44
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost (2001) 2.24
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest (1993) 2.20
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med (2000) 2.13
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol (2000) 2.11
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest (1993) 2.08
Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol (1996) 2.08
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost (1981) 1.98
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest (1985) 1.97
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development (2001) 1.92
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation (1997) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.89
On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem (1978) 1.86
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res (2002) 1.73
Molecular mechanism of physiological fibrinolysis. Nature (1978) 1.71
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta (1979) 1.69
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem (1976) 1.66
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol (2000) 1.64
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet (1985) 1.60
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med (1991) 1.58
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med (1984) 1.57
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem (1980) 1.56
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost (2005) 1.55
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55